Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Global Banking & Finance Review

Company

    GBAF Logo
    • About Us
    • Profile
    • Wealth
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2025 GBAF Publications Ltd - All Rights Reserved.

    ;
    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Finance

    AstraZeneca wins shareholder backing for NYSE listing in US pivot

    Published by Global Banking and Finance Review

    Posted on November 3, 2025

    Featured image for article about Finance

    (Reuters) -AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool.

    The drugmaker said 99.36% of votes cast in a general meeting favoured the proposal. The company needed at least 75% of votes for the resolution to pass.

    AstraZeneca, London's most valuable company, outlined plans for a much-anticipated U.S. direct listing in September, replacing its existing American depositary receipts on the Nasdaq with ordinary shares on the NYSE, while retaining its London and Stockholm listings.

    The U.S. market accounts for more than 40% of AstraZeneca's revenue, making it critical to CEO Pascal Soriot's growth strategy and future outlook amid mounting political scrutiny.

    AstraZeneca Chair Michel Demare said in a statement that the shareholder vote in favour of the board's proposal showed strong investor confidence in the company's move to streamline its listing across London, Stockholm and New York.

    He said the harmonised listing structure would give AstraZeneca greater flexibility to tap global capital markets, particularly in the U.S., as it continues to expand in high-growth regions.

    While analysts and policymakers had expressed relief that the Anglo-Swedish drugmaker's plans did not include ditching its London listing altogether, there are still concerns that the move could prompt other large companies to follow suit.

    The direct listing on the NYSE is expected to go live on February 2, 2026.

    (Reporting by Yamini Kalia and Aatrayee Chatterjee in Bengaluru; Editing by Arun Koyyur and Tomasz Janowski)

    Why waste money on news and opinions when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe